DB
David Bredt
Chief Scientific Officer

David Bredt insider trades: Rapport Therapeutics (RAPP) stock sales

Chief Scientific Officer, Rapport Therapeutics Last trade Feb 17, 2026 16 Form 4 filings
$1.1M
Sold, last 12 months
5 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2025
1
Company
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where David reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
Feb 17, 2026RAPP↓ Sell$247K
Jan 15, 2026RAPP↓ Sell$228K
Dec 31, 2025RAPP↓ Sell$197K
Dec 15, 2025RAPP↓ Sell$255K
Nov 17, 2025RAPP↓ Sell$214K
Oct 15, 2025RAPP↓ Sell$219K
Sep 15, 2025RAPP↓ Sell$206K
Aug 15, 2025RAPP↓ Sell$127K
Jul 15, 2025RAPP↓ Sell$119K
Jun 16, 2025RAPP↓ Sell$94K
May 15, 2025RAPP↓ Sell$81K
Apr 15, 2025RAPP↓ Sell$81K
Mar 14, 2025RAPP↓ Sell$92K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other RAPP insiders

Open-market trades in the last 12 months

About David Bredt's insider trades

David Bredt is Chief Scientific Officer at Rapport Therapeutics (RAPP). Since Mar 14, 2025, David has reported no open-market purchases and 13 sales worth $2.2M on SEC Form 4. In the last 12 months: 5 sales ($1.1M).

Their filings also include grants and awards (4 filings), option exercises (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RAPP insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.